Skip to content
    Vivo Capital logo

    Vivo Capital

    Palo Alto, California, United StatesFounded 1996
    vivocapital.comLinkedIn
    HealthcareBiotech & Life Sciences

    Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California. It manages a multi-strategy platform spanning venture capital, growth equity, buyout, and public equities, focused on biotechnology, pharmaceuticals, medical devices, and healthcare services.

    67% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $95.2M (across 78 rounds with reported amounts).

    Find people at Vivo Capital on Goldilocks AI

    Portfolio

    72

    Fund Size

    $740M

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    HD

    Hao Dong

    Managing Director

    KD

    Kevin Dai, Pharm.D

    Partner

    AC

    Albert Chang

    Executive Director Head Trader

    NF

    Nina Feng, M.B.A., C.F.A

    Chief Representative of Taiwan Office, Executive Director,Investor Relations

    AH

    Andrew Huang

    Principal

    JG

    Jane Gong

    Principal,Investor Relations

    JL

    Jiawei Liu

    Principal

    BS

    Brad Sunderland

    Associate,Investor Relations

    RD

    Richard Ding, M.Eng

    Analyst

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    81 investments
    CompanyRoundAmountDate
    Kinaset Therapeutics logoKinaset TherapeuticsSeries B$103MJan 2026
    BlossomHill Therapeutics logoBlossomHill TherapeuticsSeries B$84MDec 2025
    SSAB Biotherapeutics, Inc.Series B$175MJul 2025
    DDBV Technologies S.A.Unknown$306.9MMar 2025
    Surrozen logoSurrozenSeries D$175MMar 2025
    Sanegene Bio logoSanegene BioSeries B$110MJan 2025
    35 Pharma logo35 PharmaSeries C$53MNov 2024
    Ajax Therapeutics Inc. logoAjax Therapeutics Inc.Series C$95MMay 2024
    AAjax TherapeuticsSeries C$95MJan 2024
    Compass Pathways logoCompass PathwaysUnknown$285MAug 2023
    Gracell Biotechnologies logoGracell BiotechnologiesGrowth$150MAug 2023
    AAdaRx PharmaceuticalsSeries C$200MAug 2023
    Digibee logoDigibeeSeries B$60MJun 2023
    UUnicycive Therapeutics, Inc.Series A$30MMar 2023
    AAdarxSeries C$46MJan 2023
    Inspirna logoInspirnaSeries D$50MJan 2022
    Avistone Pharmaceuticals logoAvistone PharmaceuticalsSeries A$200MDec 2021
    HistoWiz logoHistoWizSeries A$32MOct 2021
    Histowiz logoHistowizSeries A$32MOct 2021
    InBrace logoInBraceSeries D$102MSep 2021
    Neurogastrx logoNeurogastrxSeries B$60MAug 2021
    Rgenta Therapeutics logoRgenta TherapeuticsSeed$18MMay 2021
    Immune Onc logoImmune OncSeries A$73MMar 2021
    Fortis Therapeutics logoFortis TherapeuticsSeries A$40MMar 2021
    Io Biotech logoIo BiotechSeries B—Jan 2021
    Page 1 of 4

    Top Co-Investors

    RA Capital Management17 shared
    OrbiMed16 shared
    venBio14 shared
    Logos Capital10 shared
    Novo Holdings A/S9 shared
    Cormorant Asset Management9 shared
    Surveyor Capital7 shared
    Pivotal Life Sciences7 shared
    Frazier Healthcare Partners7 shared
    Samsara BioCapital6 shared
    BlackRock Private Equity Partners6 shared
    Marshall Wace6 shared
    HBM Healthcare Investments6 shared
    Venrock Healthcare Capital Partners6 shared
    SR One5 shared
    Bain Capital Life Sciences5 shared
    Loyal Valley Capital4 shared
    Soleus Capital4 shared
    Asahi Kasei4 shared
    Adage Capital Management4 shared

    Last updated: 7 September 2026